Bleakley Financial Group LLC Makes New Investment in Privia Health Group, Inc. (NASDAQ:PRVA)

Bleakley Financial Group LLC bought a new position in shares of Privia Health Group, Inc. (NASDAQ:PRVA) during the 4th quarter, HoldingsChannel.com reports. The fund bought 13,246 shares of the company’s stock, valued at approximately $305,000.

Several other large investors also recently bought and sold shares of the stock. Advisors Preferred LLC purchased a new stake in Privia Health Group during the 4th quarter worth approximately $2,137,000. International Assets Investment Management LLC lifted its stake in Privia Health Group by 2,721.7% during the 4th quarter. International Assets Investment Management LLC now owns 7,139 shares of the company’s stock valued at $164,000 after acquiring an additional 6,886 shares during the period. Riverbridge Partners LLC lifted its stake in Privia Health Group by 8.7% during the 4th quarter. Riverbridge Partners LLC now owns 4,342,385 shares of the company’s stock valued at $100,005,000 after acquiring an additional 348,852 shares during the period. Trust Point Inc. acquired a new stake in Privia Health Group during the 4th quarter valued at approximately $585,000. Finally, Bell Bank lifted its stake in Privia Health Group by 49.1% during the 4th quarter. Bell Bank now owns 27,758 shares of the company’s stock valued at $639,000 after acquiring an additional 9,143 shares during the period. Hedge funds and other institutional investors own 94.48% of the company’s stock.

Insider Buying and Selling

In related news, CFO David Mountcastle sold 3,933 shares of the business’s stock in a transaction on Tuesday, April 2nd. The shares were sold at an average price of $17.77, for a total value of $69,889.41. Following the completion of the sale, the chief financial officer now owns 262,279 shares of the company’s stock, valued at approximately $4,660,697.83. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other news, Director William M. Sullivan sold 9,951 shares of the company’s stock in a transaction on Wednesday, January 24th. The shares were sold at an average price of $23.03, for a total transaction of $229,171.53. Following the completion of the sale, the director now owns 5,464,533 shares of the company’s stock, valued at $125,848,194.99. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CFO David Mountcastle sold 3,933 shares of the company’s stock in a transaction on Tuesday, April 2nd. The stock was sold at an average price of $17.77, for a total transaction of $69,889.41. Following the sale, the chief financial officer now directly owns 262,279 shares of the company’s stock, valued at approximately $4,660,697.83. The disclosure for this sale can be found here. 14.20% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several analysts have commented on the stock. Barclays assumed coverage on shares of Privia Health Group in a research note on Wednesday, March 6th. They set an “equal weight” rating and a $22.00 price objective for the company. JPMorgan Chase & Co. decreased their price objective on shares of Privia Health Group from $38.00 to $30.00 and set an “overweight” rating for the company in a research note on Wednesday, March 6th. Canaccord Genuity Group decreased their price objective on shares of Privia Health Group from $41.00 to $37.00 and set a “buy” rating for the company in a research note on Tuesday, March 19th. Jefferies Financial Group initiated coverage on shares of Privia Health Group in a research note on Monday, February 26th. They set a “buy” rating and a $25.00 price objective for the company. Finally, Bank of America cut shares of Privia Health Group from a “buy” rating to a “neutral” rating and decreased their target price for the company from $27.00 to $21.00 in a research note on Thursday, February 22nd. Two research analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to data from MarketBeat.com, Privia Health Group has a consensus rating of “Moderate Buy” and an average price target of $28.18.

Privia Health Group Stock Performance

Shares of NASDAQ PRVA opened at $18.35 on Tuesday. The firm has a market cap of $2.18 billion, a PE ratio of 96.58, a PEG ratio of 2.53 and a beta of 0.81. The firm has a fifty day moving average of $20.29 and a 200 day moving average of $21.52. Privia Health Group, Inc. has a one year low of $17.54 and a one year high of $30.15.

Privia Health Group (NASDAQ:PRVA) last issued its quarterly earnings results on Tuesday, February 27th. The company reported $0.02 EPS for the quarter, missing the consensus estimate of $0.04 by ($0.02). The company had revenue of $440.80 million during the quarter, compared to analysts’ expectations of $425.81 million. Privia Health Group had a return on equity of 3.97% and a net margin of 1.39%. Privia Health Group’s revenue was up 21.0% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.14 EPS. On average, equities analysts predict that Privia Health Group, Inc. will post 0.26 EPS for the current fiscal year.

About Privia Health Group

Privia Health Group, Inc operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings.